Alpha Profiles · Company Profile

Ultragenyx Pharmaceutical Inc.

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/ultragenyx-pharmaceutical-inc

Entity: Public listing published
Primary listing: NASDAQ: RARE
Verification: Partially verified
Last reviewed: 2026-09-16T04:46:00.818683+00:00

Overview

Alpha's canonical identity and public leadership record for Ultragenyx Pharmaceutical Inc..

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

7 public records

Dennis Huang

Chief Technical Operations Officer and Gene Therapy and Executive Vice President

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001308179-26-000174Mar 27, 2026

Emil D. Kakkis, M.D., Ph.D.

President and Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001308179-26-000174Mar 27, 2026

Eric Crombez, M.D.

Chief Medical Officer and Executive Vice President

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001308179-26-000174Mar 27, 2026

Erik Harris

Chief Commercial Officer and Executive Vice President

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001308179-26-000174Mar 27, 2026

Howard Horn

Chief Financial Officer, Corporate Strategy and Executive Vice President

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001308179-26-000174Mar 27, 2026

John R. Pinion II

Chief Quality Officer and Executive Vice President of Translational Sciences

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001308179-26-000174Mar 27, 2026

Karah Parschauer

Chief Legal Officer & Corporate Affairs and Executive Vice President

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001308179-26-000174Mar 27, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 16, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.